Among patients with R/R AML, 14 (74%) harbored IDH2 p.R140Q and 5 (26%) had IDH2 p.R172K mutations with median VAFs of 23% (range, 3–50%), and 35% (range, 18–46%), respectively. This evidence concerns the gene IDH2 and acute myeloid leukemia.